+1-786-628-7980
Sign Up/Sign In 
The Global HIV Rapid Testing Market size is predicted to reach $15.07 billion by 2030, growing at a CAGR of 7.22% during the forecast period 2024-2030 according to the latest market research report published by IndustryARC. Increasing prevalence of HIV, Government initiatives and Development of innovative HIV are the driving factors of the market are fueling the growth of the HIV Rapid Testing Market during the forecast period, finds IndustryARC in its recent report, titled “HIV Rapid Testing Market Size, Share & Trends Analysis Report By HIV Type (HIV 1, HIV 2), By Sample Type (Blood (Fingerstick, Venous Blood Draw), Oral Fluid, Serum, Plasma, Urine), By Test Types (Antibody Rapid Test, Antigen Rapid Test, Antigen/Antibody Combination Test), By Technology (Immunofiltration, Lateral Flow Immunoassay, Enzyme-Linked immunosorbent assay (ELISA), Chemiluminescent Immunoassay (CLIA), Fluorescence Immunoassay (FIA)), By Geography – Global Opportunity Analysis & Industry Forecast, 2024-2030.
Request Sample Research Report: https://www.industryarc.com/pdfdownload.php?id=800569
Asia-Pacific to Register Highest Growth:
Geographically, in the global HIV Rapid Testing Market share, Asia-Pacific is analyzed to grow with the highest CAGR of 8.91% during the forecast period 2024-2030. The Asia-Pacific (APAC) region has emerged as the epicenter of substantial growth in the HIV Rapid Testing Market, largely attributed to proactive measures taken by governments such as Vietnam. The Vietnamese government’s concerted efforts to expand access to HIV testing and treatment have significantly contributed to this positive trajectory. In recent years, a targeted approach has been adopted, focusing on key populations at higher risk of HIV transmission, including individuals who inject drugs, men who have sex with men, and sex workers. By prioritizing these populations, the government aims to enhance early detection and treatment outcomes. Notably, the provision of free HIV testing and antiretroviral therapy (ART) to those in need has played a pivotal role in fostering a comprehensive and accessible healthcare infrastructure. As a result, these initiatives have become instrumental in fueling the growth of the HIV Rapid Testing Market across the Asia-Pacific region, underscoring the significance of tailored public health interventions in shaping the market landscape.
HIV Rapid Testing Market 2023-2030: Scope of the Report
|
Report Metric |
Details |
|
Base Year Considered |
2023 |
|
Forecast Period |
2024–2030 |
|
CAGR |
7.22% |
|
Market Size in 2030 |
$15.07 billion |
|
Segments Covered |
HIV Type, Sample Type, Test Type, Technology, Demographics, Test Generation, Application, End User, Distribution Channel |
|
Geographies Covered |
North America (U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia, New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), Rest of the World (Middle East and Africa). |
|
Key Market Players |
1. Abbat 2. F.Hoffmann-La Roche AG 3. Bio-Rad Laboratories, Inc 4. Siemens Healthineers 5. Hologic Inc 6. Orasure Technologies, Inc 7. Danaher (Including Cephied) 8. BioMerieux Clinical Diagnostics 9. Quidel Corporation 10. Chembio Diagnostic Systems |
Get Access to Full Research Report:
https://www.industryarc.com/Research/hiv-rapid-testing-market-research-800569
HIV Rapid Testing Market Report – Key Takeaways:
HIV testing services are vital in preventing the spread of the virus, and they can be categorized as either conventional facility-based or community-based. Facility-based testing, as outlined in a WHO facts sheet from July 2022, encompasses tests conducted at health facilities either upon client request or through healthcare provider-initiated testing and counseling. The global HIV landscape reflects the significance of testing, with 38.4 million people living with HIV at the end of 2021 and 1.5 million new infections. These kits contribute to early detection, preventing further transmission and facilitating prompt medical intervention. Consequently, the HIV rapid testing market, particularly the Facility Administered Kit segment, witnessed significant growth, generating $644.77 million in revenue in 2022. Projections indicate further expansion, with an expected revenue of $1081.40 million by 2030, showcasing a notable compound annual growth rate (CAGR) of 6.64% during the period from 2024 to 2030.
Lateral Flow Immunoassay plays a pivotal role in the realm of rapid HIV testing, employing HIV 1 subtype B antigens to capture HIV-specific antibodies, primarily from the immunodominant transmembrane region., The Lateral Flow Immunoassay segment is poised for expansion, driven by the increasing demand for point-of-care testing. Notably, the rapidity of results and cost-effectiveness compared to alternative technologies contribute to the growth of the HIV rapid testing market. In 2022, the Lateral Flow Immunoassay segment generated a substantial revenue of $634.2 million, with projections indicating further growth to reach $1128.31 million by 2030, exhibiting a noteworthy compound annual growth rate (CAGR) of 7.43%.
The burgeoning HIV prevention and treatment programs implemented by governments worldwide are pivotal drivers behind the growth of the HIV Rapid Testing market
Many countries have implemented test and treat strategy program. According to the program, person who tests positive for HIV is immediately offered antiretroviral therapy (ART), regardless of their CD4 cell count. This approach has been shown to improve health outcomes and reduce HIV transmission. According to World Health Organization, the Ghana national strategic plan for HIV 2021–2025 includes ambitious 95%-95%-95% HIV testing, treatment, and viral suppression targets. Thus the implementation of such programs can accelerate the demand for HIV rapid testing.
Despite the steady growth of the HIV Rapid Testing Market, several issues pose challenges that may impact its further expansion. Concerns related to false positives and false negatives, limited sensitivity and specificity, and the persistent issue of stigma are prevalent in HIV Rapid Testing. Rapid tests, on occasion, may yield inaccurate results, leading to false positives or false negatives, which can result in incorrect diagnosis and treatment. Moreover, these tests may lack the sensitivity and specificity of traditional laboratory-based tests, further contributing to the risk of inaccurate results, thereby undermining public trust in testing services and raising ethical concerns.
Additionally, the regulatory landscape for HIV rapid testing is complex and can vary significantly across different regions and countries. This variability may limit the availability and accessibility of testing services, posing additional challenges to market growth. Addressing these issues is crucial for fostering confidence in HIV testing services and ensuring the continued expansion of the market.
Purchase this Premium Report:
https://www.industryarc.com/purchasereport.php?id=800569
Key Opportunity Analysis:
Growing demand of Multiplex HIV Rapid Testing can create opportunities for the growth of the market
The escalating demand for Multiplex HIV Rapid Testing is poised to unlock significant opportunities for the growth of the HIV Rapid Testing market in the forecast period. Multiplex HIV rapid testing is gaining prominence due to its inherent advantages over traditional single-antigen tests. Unlike single-antigen tests, Multiplex HIV rapid tests have the capability to simultaneously detect two or more HIV antigens or antibodies in a single sample, providing heightened accuracy and reliability in results. This advanced testing approach offers benefits such as higher accuracy, faster results, cost-effectiveness, ease of use, and enhanced flexibility.
In January 2022, Bio-Rad Laboratories, Inc. introduced the BioPlex 2200 HIV Ag-Ab assay, a groundbreaking fully automated multiplex test. This innovative assay has the capability to simultaneously detect HIV-1 p24 antigen and antibodies to both HIV-1 and HIV-2 in human serum or plasma, utilizing the advanced BioPlex 2200 System. Multiplex HIV Rapid testing, as exemplified by this assay, enables the simultaneous detection of multiple infections, including HIV, in a single test. This not only streamlines the testing process but also saves valuable time and resources. The introduction of such advanced technologies is poised to create lucrative opportunities for market growth, offering healthcare providers the means to conduct more comprehensive testing and improve patient care.
Raise of Next-Generation HIV Test Technology
The rise of fourth-generation rapid test kits has become more popular in recent years. This technology is more accurate and reliable for screening the acute HIV presence in the sample. The 4th generation HIV test easily detects HIV in lesser time and more accurately than other generation technologies. Such factors allow individuals to get a cure sooner and potentially prevent the spread of infection to others. One of the leading HIV rapid test kit market players, OraSure technologies, got approval for a home test kit known as “OraQuick In-Home HIV Test,” which gives results in 20 to 40 minutes.
Increasing Targeted Patient Population
In 2022, approximately 15 million individuals contracted HIV, and by 2025, the global estimate of people living with HIV exceeded 38 million. This surge in HIV cases has prompted an escalation in preventive measures, particularly the use of self-test kits to expand the reach of HIV testing. The demand for HIV testing is notably on the rise in regions with high infection rates, such as Africa, Europe, and various Asian countries. This heightened demand for HIV rapid test kits is driving market growth as it addresses the increasing need for accessible and efficient testing methods in regions heavily impacted by the virus.
If you have any questions, please feel free to contact our experts at: https://www.industryarc.com/reports/request-quote?id=800569
The Report also Covers the Following Areas:
HIV Rapid Testing Market 2023-2030: Key Highlights
Covid and Ukrainian Crisis Impact:
The COVID-19 pandemic has left an indelible mark on global healthcare, impacting various facets of diagnostic testing, including the HIV rapid testing market. The disruptions caused by lockdowns and social distancing measures have led to a reduction in routine healthcare services, affecting the accessibility of HIV testing. Individuals’ hesitancy or inability to seek in-person healthcare services has contributed to a decline in testing rates, potentially resulting in delayed or missed HIV diagnoses. The reprioritization of healthcare resources and funding towards managing the immediate challenges posed by COVID-19 has led to a shift in priorities, affecting the implementation of HIV testing programs. Despite these challenges, the pandemic has spurred innovations, with an increased emphasis on telehealth services and self-testing options.
The ongoing crisis in Ukraine has the potential to impact various sectors, including healthcare, and may influence the landscape of the HIV rapid testing market in several ways. Disruptions in healthcare infrastructure due to conflict-related damage, shortages of medical supplies, and the displacement of healthcare professionals can hinder the availability and accessibility of healthcare services, including HIV testing. The crisis-induced population displacement and vulnerability may make at-risk populations more susceptible to health challenges, limiting their access to testing facilities and healthcare resources. Resource diversion towards addressing immediate humanitarian needs and emergency healthcare may result in a redirection of funds and attention away from routine healthcare programs, impacting HIV testing initiatives.
To Get a Customized Industry Analysis, Speak with our Research Analyst: https://connect.industryarc.com/lite/schedule-a-call-with-our-sales-expert
List of Key Market Players in HIV Rapid Testing Market:
The key companies profiled in the HIV Rapid Testing Market Report are listed below:
Related Reports:
Prostate Cancer Testing Kits Market – Prostate Cancer Testing Kits Market size is estimated to reach $1.9 billion by 2027, growing at a CAGR of 11.4% during the forecast period 2022-2027. The earliest step in testing for prostate cancer is a prostate-specific antigen (PSA) test. PSA is a protein prepared by the prostate, the tiny gland below the bladder. In certain cases, an elevated PSA level can be a sign of prostate cancer. However, not all elevated PSA levels are an indication of prostate cancer.
China Testing, Inspection & Certification Market – China Testing, Inspection & Certification Market caters to a diverse range of industries in China with its wide spectrum of standard, regulation and legislation’s. China Testing, Inspection & Certification Market is expected to grow at a CAGR of 6.5% during 2021-2026 and is likely to reach $38.5 billion by 2026. Due to the COVID-19 pandemic of 2020, the demand for automotive and consumer products industry fell dramatically, as supply chains for raw materials were disrupted due to lockdowns and logistics issues and also as many consumers have been staying at home, the need or interest to purchase new devices also dropped
The Gonorrhea Diagnostics Market – The Gonorrhea Diagnostics Market is estimated to reach $13.6 billion by 2028, growing at a CAGR of 8.9% over the forecast period 2023-2028. Gonorrhea is a sexually transmitted infection afflicted by a bacterium that can affect both genders. Most often, gonorrhea impacts the urethra, rectum or throat. The recommended treatment for gonorrhea includes fluoroquinolone and ciprofloxacin. Cephalosporins, ceftriaxone (intramuscular) or cefixime (oral) are the recommended alternatives.
About IndustryARC™:
IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets.
IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format which assists an intelligent and informed decision-making process.
Contact Us:
Mr. Venkat Reddy
IndustryARC
Email: sales@industryarc.com
USA: (+1) 518 282 4727
